Bendamustine in multiple myeloma

European Journal of Haematology

Volumn 95, Issue 5, 2015, Pages 377-388

  Gentile, Massimo ^a   Vigna, Ernesto ^a   Recchia, Anna Grazia ^a   Morabito, Lucio ^b   Mendicino, Francesco ^a   Giagnuolo, Giovanna ^a   Morabito, Fortunato ^a  

^a Biotechnology Research Unit   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Bendamustine; Efficacy; Multiple myeloma; Safety; Therapy

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; COMPASSIONATE USE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; MONOTHERAPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION; UNSPECIFIED SIDE EFFECT; AUTOGRAFT; MORTALITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROCEDURES; TRANSPLANTATION CONDITIONING;

AUTOGRAFTS; BENDAMUSTINE HYDROCHLORIDE; HUMANS; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

EID: 84944446939     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12609     Document Type: Review

References (66)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
2. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
3. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60.
4. National Cancer Institute. Surveillance epidemiology and end results program. SEER stat fact sheets on multiple myeloma. 2013. http://seer.cancer.gov/statfacts/html/mulmy.html (accessed April 24, 2013)
5. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M. Patterns of survival in multiple myeloma: a population based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993-9.
6. Brenner H, Gondos A, Pulte D. Recentmajor improvement in long-term survivalof younger patients with multiplemyeloma. Blood 2008;111:2521-6.
7. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiplemyeloma and the impact of novel therapies. Blood 2008;111:2516-20.
8. Palumbo A, Attal M, Roussel M. Shiftsin the therapeutic paradigm for patients newly diagnosed with multiple myeloma:maintenance therapy and overall survival. Clin Cancer Res 2011;17:1253-63.
9. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plusdexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet 2010;376:2075-85.
10. Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010;11:934-41.
11. Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist 2011;16:1600-3.
12. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26:149-57.
13. Pratt G, Bowcock S, Lai M, et al. United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma. Int J Lab Hematol 2014;36:20-28.
14. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492-501.
15. Ozegowski W, Krebs D. IMET3393 ([1methyl-5-bis-(b-chloroethyl)- aminobenz-imidazolyl-(2)]-butyric acid hydrochloride, a new cytotoxic agent from among the series of benzimidazole mustard compounds [in German]. Zbl Pharm 1971;110:1013-9.
16. Ogura M, Uchida M, Taniwaki M, et al. Phase I and pharmacokinetic study of bendamustine in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010;101:2054-8.
17. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, Niemeyer CC. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanism features compared with other alkylating agent. Clin Cancer Res 2008;14:309-17.
18. Roué G, López-Guerra M, Milpied P, Pérez-Galán P, Villamor N, Montserrat E, Campo E, Colomer D. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008;14:6907-15.
19. Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol 2010;66:413-23.
20. Hartmann M, Zimmer C. Investigationof cross-link formation in DNA by thealkylating, cytostatic IMET 3106, 3393 and 3943. Biochim Biophys Acta 1972;287:386-9.
21. Haase D, Preiss R, Sohr R. UntersuchungenzurPlasmaeiweissbindung von Bendamustine(Cytostasan) und Ambazon. Z Klein Med 1990;45:1267-72.
22. Preiss R, Sohr R, Matthias M, Brockmann B, Hüller H. The pharmacokinetics of bendamustine (Cytostasan) in humans. Pharmazie 1985;40:782-4.
23. Chovan JP, Li F, Yu E, Ring SC. Metabolic profile of [(14)C]bendamustine in rat urine and bile:preliminary structural identification of metabolites. Drug Metab Dispos 2007;35:1744-55.
24. Gandhi V. Metabolism and mechanism of action of bendamustine: rationales for combination therapy. Semin Oncol 2002;29(Suppl 13):4-11.
25. Owen JS, Melhem M, Passarell JA, D'Andrea D, Darwish M, Kahl B. Bendamustine pharmacokinetic profile and exposure response relationship in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2010;66:1039-49.
26. Teichert J, Sohr R, Hennig L, Baumann F, Schoppmeyer K, Patzak U, Preiss R. Identification and quantitation of the Nacetyl- L-cysteine S-conjugates of bendamustine and its sulfoxides in human bile after administration of bendamustine hydrochloride. Drug Metab Dispos 2009;37:292-301.
27. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas. J Cancer Res Clin Oncol 2002;128:603-9.
28. ® [prescribing information] Bendamustine hydrochloride for injection for intravenous infusion. Cephalon, Inc: Frazer (PA), 2009 April. http://www.treanda.com/300-nhl-home.aspx.
29. Elefante A, Czuczman MS. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Health Syst Pharm 2010;67:713-23.
30. Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287-8.
31. Michael M, Bruns I, Bölke E, Zohren F, Czibere A, Safaian NN, Neumann F, Haas R, Kobbe G, Fenk R. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010;15:13-9.
32. Damaj G, Malard F, Hulin C, et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma 2012;53:632-4.
33. Grey-Davies E, Bosworth JL, Boyd KD, Ebdon C, Saso R, Chitnavis D, Mercieca JE, Morgan GJ, Davies FE. Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br J Haematol 2012;156:552-5; author reply 555.
34. Pönisch W, Rozanski M, Goldschmidt H, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a phase I clinical trial. Br J Haematol 2008;143:191-200.
35. Lau IJ, Smith D, Aitchison R, Blesing N, Roberts P, Peniket A, Yong K, Rabin N, Ramasamy K. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Ann Hematol 2015;94:643-9.
36. Schey S, Brown SR, Tillotson AL, et al. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUK one randomized dose selection trial. Br J Haematol 2015. doi: 10.1111/bjh.13435. [Epub ahead of print].
37. Lentzsch S, O' Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012;119:4608-13.
38. Pönisch W, Heyn S, Beck J, et al. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. Br J Haematol 2013;162:202-9.
39. Pozzi S, Badiali S, Corso A, et al. Bendamustine, low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed multiple myeloma confirms very promising results in a phase I/II study. Blood 2013;122:3212.
40. Mey U, Brugger W, Bargetzi M, et al. Multicenter phase II trial of Bendamustine, Lenalidomide and Dexamethasone (BRd) as 2nd-line therapy for multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2014;124:4779.
41. Zhang S, Wang X, Chen L, et al. Synergistic activity of bendamustine in combination with doxorubicin and bortezomib in multiple myeloma cell. Blood (ASH Annual Meeting Abstracts) 2008;112:5171.
42. Hrusovsky I, Heidtmann HH. Combination therapy of bortezomib with bendamustin in elderly patients with advanced multiple myeloma. Clinical observation. Blood (ASH Annual Meeting Abstracts) 2007;110:4851.
43. Fenk R, Michael M, Zohren F, Graef T, Czibere A, Bruns I, Neumann F, Fenk B, Haas R, Kobbe G. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007;48:2345-51.
44. Berenson JR, Yellin O, Bessudo A, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 2013;160:321-30.
45. Pönisch W, Bourgeois M, Moll B, et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 2013;139:499-508.
46. Offidani M, Corvatta L, Maracci L, et al. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J 2013;3:e162.
47. Offidani M, Maracci L, Corvatta L, et al. Bendamustine, Bortezomib and Dexamethasone (BVD) in patients with relapsed-refractory multiple myeloma (MM): updated results of a multicenter phase II study. Blood (ASH Annual Meeting Abstracts) 2014;124:4734.
48. Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine, bortezomib-dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014;123:985-91.
49. Rodon P, Hulin C, Pegourie B, et al. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. Bendamustine, bortezomib and dexamethasone (BVD) In elderly patients with multiple myeloma in first relapse: final analysis of the Intergroupe Francophone Du Myelome (IFM) 2009-01 trial. Haematologica 2015;100:e56-9.
50. AguadoBueno B, Andres IV, Entrena L, et al. Preliminary experience of the Spanish compassionate use registry of bendamustine in patients with relapsed and/or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2012;120:4035.
51. Musto P, Fraticelli VL, Mansueto G, et al. Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon. Leuk Lymphoma 2015;3:1-4.
52. Pönisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006;132:205-12.
53. Mateos MV, Oriol A, Rosiñol L, et al. Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. Haematologica 2015. pii: haematol.2015.124818. [Epub ahead of print].
54. Pönisch W, Holzvogt B, Plötze M, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. J Cancer Res Clin Oncol 2014;140:1947-56.
55. Pönisch W, Andrea M, Wagner I, et al. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol 2012;138:1405-12.
56. Pönisch W, Moll B, Bourgeois M, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. J Cancer Res Clin Oncol 2013;139:1937-46.
57. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2009;28:4976-84.
58. Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol 2011;155:632-4.
59. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma .Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
60. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
61. Pönisch W, Wiesler J, Wagner I, et al. Impact of bendamustine pretreatment on stem cell mobilization and autologous stem cell transplantation in patients with multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2011;118:1933.
62. Poenisch W, Plötze M, Holzvogt B, et al. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. J Cancer Res Clin Oncol 2015. [Epub ahead of print].
63. Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2013;19:831-7.
64. Martino M, Messina G, Moscato T, et al. Bendamustine plus melphalan as conditioning regimen for second autologous stem cell transplantation in patients with multiple myeloma: single centre experience. Blood (ASH Annual Meeting Abstracts) 2014;124:2516.
65. Breitkreutz I, Becker N, Benner A, Kosely F, Heining C, Hillengass J, Egerer G, Ho AD, Goldschmidt H, Raab MS. Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function. Hematol Oncol 2015. doi: 10.1002/hon.2199. [Epub ahead of print].
66. Napp Pharmaceuticals Limited. Levact 2.5 mg/ml powder for concentrate for solution for infusion. Summary of product characteristics [online]. www.medicines.org.uk/emc/medicine/23469.